Although in our study there was no information regarding treatment follow-up and none of the patients from whom we obtained samples had participated in clinical trials evaluating inhibitor PIK3CA or mTOR inhibitors, this form of tumor analysis could support stratification in a prospective clinical trial evaluating the clinical benefit of (dual) PIK3CA/mTOR treatments in comparison with current standard treatments. The gene discussed is PIK3CA; the disease is neoplasm.